BOSTON – May 3, 2022: CureLab Oncology , a clinical-stage biotech company, has been granted a patent in South Korea for the treatment of non-cancerous diseases of chronic inflammation with its lead product, the DNA plasmid coding p62/SQSTM1 gene (p62). Chronic inflammation is an underlying condition that manifests itself in different organs and tissues as a multitude of diseases.
CureLab’s research has been focused on a new strategy for treatment of various diseases that involve chronic inflammation in their pathogenesis. CureLab’s lead product, Elenagen™, reduces chronic inflammation. In its ongoing cancer clinical studies, CureLab has observed a desirable safety profile and preliminary evidence of clinical benefits of Elenagen for cancer patients.
Based on this research, the company is planning to initiate clinical trials testing its lead product as an anti-cancer agent against psoriasis, osteoporosis, metabolic syndrome/type 2 diabetes, cardiovascular, CNS, lupus, and psychiatric diseases.
With a population of 51 million, South Korea is the world’s tenth-largest economy. South Koreans have access to excellent universal healthcare, access to which is ranked first in the OECD. The life expectancy of South Koreans is currently over 82 years and rising. Taken together, these factors make this new patent of high economic potential for CureLab Oncology
CureLab Oncology Inc. is a pre-IPO, clinical-stage immuno-oncology biotech company headquartered near Boston, Massachusetts. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelab.com.
Tim Cox, ZingPR, email@example.com